AAAAAA

   
Results: 1-3 |
Results: 3
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
Authors: van der Valk, M Gisolf, EH Reiss, P Wit, FWNM Japour, A Weverling, GJ Danner, SA
Citation: M. Van Der Valk et al., Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection, AIDS, 15(7), 2001, pp. 847-855
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
Authors: Murphy, RL Brun, S Hicks, C Eron, JT Gulick, R King, M White, AC Benson, C Thompson, M Kessler, HA Hammer, S Bertz, R Hsu, A Japour, A Sun, E
Citation: Rl. Murphy et al., ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results, AIDS, 15(1), 2001, pp. F1-F9
A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
Authors: Colgrove, R Japour, A
Citation: R. Colgrove et A. Japour, A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance, ANTIVIR RES, 41(1), 1999, pp. 45-56
Risultati: 1-3 |